Get the Stockscreener App
5.66
5.20%
0.28
Coya Therapeutics Inc stock is traded at $5.66, with a volume of 34,524.
It is up +5.20% in the last 24 hours and up +8.02% over the past month.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
See More
Previous Close:
$5.38
Open:
$5.5
24h Volume:
34,524
Relative Volume:
0.37
Market Cap:
$94.56M
Revenue:
-
Net Income/Loss:
$-12.36M
P/E Ratio:
-4.524
EPS:
-1.2511
Net Cash Flow:
$-11.39M
1W Performance:
+0.18%
1M Performance:
+8.02%
6M Performance:
-19.14%
1Y Performance:
-5.19%
1-Day Range:
$5.32
$5.66
1-Week Range:
$5.32
$5.89
52-Week Range:
$4.75
$10.69
Coya Therapeutics Inc Stock (COYA) Company Profile
Name
Coya Therapeutics Inc
Sector
Industry
Phone
650.739.3939
Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
5.66 | 94.56M | 0 | -12.36M | -11.39M | -1.2511 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-24 | Initiated | D. Boral Capital | Buy |
Coya Therapeutics Inc Stock (COYA) Latest News
Coya Therapeutics (NASDAQ:COYA) Given “Buy” Rating at D. Boral Capital - Defense World
Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital - MarketBeat
EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases - AOL
Coya Therapeutics advances COYA 303 for inflammatory diseases - Investing.com India
Coya Therapeutics Unveils COYA 303: Novel GLP-1 Combination Therapy for Inflammatory Diseases - StockTitan
Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 10.2% in December - MarketBeat
Revolutionizing Success in the AI in Clinical Trials Market: - openPR
Geode Capital Management LLC Has $918,000 Stake in Coya Therapeutics, Inc. (NASDAQ:COYA) - Defense World
How to Take Advantage of moves in (COYA) - Stock Traders Daily
Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from D. Boral Capital - MarketBeat
Coya Therapeutics enrolls five in FTD study, eyes Phase 2 trial - Investing.com
Objective long/short (COYA) Report - Stock Traders Daily
Regulatory T-cells (Tregs) Therapies Market Key Players - openPR
Factors Influencing Global Regulatory T Cell Tregs Therapies - openPR
Exosome Therapeutics Market Applications in Neurological - openPR
Boral Capital initiates coverage on Coya Therapeutics with Buy rating By Investing.com - Investing.com Canada
Coya Therapeutics (NASDAQ:COYA) Now Covered by D. Boral Capital - MarketBeat
INNOVATIONMAP EMAILS ARE AWESOME - InnovationMap
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference - StockTitan
Alzheimer’s Disease Market Size to Reach US$ 6.3 Billion by 2034, Impelled by Advancements in Early Detection - IMARC Group
Coya Therapeutics files to sell 1.38M shares of common stock for holders - MSN
Coya Therapeutics sets sights on neurodegenerative trials in 2025 - Investing.com India
Coya Therapeutics Advances $700M ALS Program, Sets Key 2025 Clinical Milestones | COYA Stock News - StockTitan
Trend Tracker for (COYA) - Stock Traders Daily
Insider Buying: CFO David Snyder Acquires Shares of Coya Therape - GuruFocus.com
Coya therapeutics CFO David Snyder buys $12,934 in stock - Investing.com
HC Wainwright Has Positive Forecast for COYA FY2024 Earnings - MarketBeat
Insider Buying: Coya Therapeutics Inc (COYA) Sees Purchase from Chief Medical Officer - GuruFocus.com
Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Announces Earnings Results - MarketBeat
The Friday Biotech Perspective #32 - substack.com
Meet 5 of the fastest-growing scaleup companies in Houston - InnovationMap
Coya Therapeutics' (COYA) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Coya Therapeutics Reports Q3 2024 Highlights and Progress - TipRanks
Coya Therapeutics board member resigns due to new job policy By Investing.com - Investing.com Canada
Coya Therapeutics Advances Pipeline for Neurodegenerative Diseases - TipRanks
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results - The Bakersfield Californian
Coya Therapeutics board member resigns due to new job policy - Investing.com India
Long Term Trading Analysis for (COYA) - Stock Traders Daily
Arun Swaminathan assumes new role as chief executive officer of Coya Therapeutics - pharmabiz.com
Coya Therapeutics appoints new CEO amid Alzheimer's trial progress By Investing.com - Investing.com South Africa
Coya Therapeutics, Inc. (NASDAQ:COYA) Sees Significant Increase in Short Interest - MarketBeat
Coya Therapeutics appoints new CEO amid Alzheimer's trial progress - Investing.com
Coya Therapeutics Promotes Arun Swaminathan, Ph.D. to Chief Executive Officer - citybiz
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer - StockTitan
Coya Therapeutics announces executive changes - Investing.com India
Coya Therapeutics Announces Leadership Change and New CEO - TipRanks
Coya Therapeutics announces executive changes By Investing.com - Investing.com UK
Coya Therapeutics On Developing A Combination Biologic - BioProcess Online
Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off (NASDAQ:COYA) - Seeking Alpha
Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results - Yahoo Finance
Coya Therapeutics Inc Stock (COYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):